Cavalier Investments’s iRadimed IRMD Stock Holding History

Cavalier Investments’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-48,247	Closed	-$987K	–	129
2019 Q2	$987K	Hold	48,247	–	–	0.41%	58
2019 Q1	$1.35M	Hold	48,247	–	–	0.56%	51
2018 Q4	$1.18M	Buy	48,247 +17,647	+58%	+$474K	0.38%	45
2018 Q3	$1.14M	Buy	+30,600	New	+$826K	0.33%	68
2016 Q3	–	Sell	-10,000	Closed	-$218K	–	148
2016 Q2	$218K	Hold	10,000	–	–	0.13%	109
2016 Q1	$192K	Hold	10,000	–	–	0.11%	96
2015 Q4	$280K	Buy	+10,000	New	+$283K	0.17%	89

Other funds holding IRMD

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMC

RK Capital Management (Colorado) Denver, Colorado $324K AUM 47.52% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

CCM

Cadence Capital Management Boston, Massachusetts $415M AUM 11.01% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Cavalier Investments's IRMD Position: Q3 2019 in Review

Cavalier Investments sold out of iRadimed (IRMD) in Q3 2019, closing a stake of 48,247 shares — an estimated $987K sold.

Cavalier Investments first reported a position in IRMD in Q4 2015 and held it in 7 quarters. The position peaked at $1.35M in Q1 2019. 59 funds tracked by Wall St. Rank hold IRMD as of Q3 2019.

Cavalier Investments reported no remaining iRadimed position as of Q3 2019 after selling out during the quarter.
Cavalier Investments sold 48,247 iRadimed shares in Q3 2019, an estimated $987K.
Cavalier Investments first reported a position in iRadimed in Q4 2015 and held it in 7 quarters.
Cavalier Investments's iRadimed position peaked at $1.35M in Q1 2019.
59 funds tracked by Wall St. Rank held iRadimed as of Q3 2019.

Based on Cavalier Investments's 13F filing for Q3 2019, filed 6 Nov 2019.